Rezolute (RZLT) Short term Debt (2011 - 2021)

Rezolute's (RZLT) quarterly Short term Debt came in at $1.8 million in Q1 2021, up 2007677.78% quarter-over-quarter from $90.0 in Q4 2017.

Rezolute (RZLT) Short term Debt (2011 - 2021) Analysis & Trends

Rezolute has disclosed Short term Debt across 8 years of filings, most recently posting $1.8 million for Q1 2021.

Short term Debt for Q1 2021 came in at $1.8 million, changed N/A year-over-year; the trailing twelve-month figure through Mar 2021 was $1.8 million (changed N/A YoY), and the FY2017 annual result was $588.0, down 95.08% from the prior year.
Short term Debt came in at $1.8 million for Q1 2021 at Rezolute, up from $90.0 in the prior quarter.
In the past five years, Short term Debt ranged from a high of $1.8 million in Q1 2021 to a low of $90.0 in Q4 2017.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Alterity Therapeutics	925,601.88 Bn	925,601.85 Bn	-
2	Belite Bio	58,560.00 Bn	58,560.00 Bn	-
3	Quantum Biopharma	17,284.41 Bn	17,284.40 Bn	-
4	Legend Biotech	2,809.00 Bn	2,808.71 Bn	242.10 Mn
5	Evaxion A	1,334.43 Bn	1,334.42 Bn	-
6	Akari Therapeutics	1,312.27 Bn	1,312.26 Bn	-
7	Psyence Biomedical	212.16 Bn	212.16 Bn	-
8	Vertex Pharmaceuticals	114.83 Bn	107.58 Bn	2.59 Bn
9	Abivax	91.96 Bn	91.96 Bn	-
10	Rezolute	520.13 Mn	520.13 Mn	-

Download Data